This was associated with a concurrent reduction in seizure frequency and fatality following ASO-TANGO treatment in a mouse model of Dravet syndrome.7 A similar method used an oligonucleotide-derived compound (AntagoNAT) to knock-down antisense noncoding RNA that suppresses Scn1a expression. The gene discussed is SCN1A; the disease is encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy.